Spyre Therapeutics
Elisabeth Kurkimilis brings extensive experience in clinical operations, currently serving as Executive Director of Clinical Operations at Prometheus Biosciences, Inc. since March 2021, after a notable tenure at Celgene from May 2005 to January 2022, where roles included Director and Senior Director overseeing global clinical trials. Prior to Celgene, Elisabeth held key positions at Bristol-Myers Squibb, Endo Pharmaceuticals, Aventis, and Rhone-Poulenc Rorer, gaining expertise in managing complex clinical trials across various compounds. Elisabeth earned a Bachelor of Science degree in Microbiology from the University of South Florida.
This person is not in any teams
Spyre Therapeutics
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.